Related Experiment Video
Updated: Aug 11, 2026
09:05
In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
Published on: August 20, 2016
Clinical studies with matrix metalloproteinase inhibitors
1Department of Clinical Research, British Biotech Pharmaceuticals Ltd., Oxford, UK.
Summary
Matrix metalloproteinase (MMP) inhibitors show promise in preventing cancer invasion and spread. Early clinical trials suggest these oral medications are well-tolerated, with further studies ongoing.
Area of Science:
- Oncology
- Biochemistry
Background:
- Matrix metalloproteinases (MMPs) play a crucial role in tumor invasion and metastasis.
- Targeting MMPs is a potential strategy for cancer therapy.
Purpose of the Study:
- To investigate the efficacy and safety of matrix metalloproteinase (MMP) inhibitors in cancer treatment.
- To evaluate the potential of MMP inhibitors in preventing tumor invasion and metastasis.
Main Methods:
- Synthesis of potent and selective MMP inhibitors.
- In vitro studies assessing tumor invasion.
- In vivo studies using animal cancer models to evaluate tumor growth and metastasis.
- Phase I clinical trials to assess safety and tolerability of oral MMP inhibitors.
Main Results:
- MMP inhibitors demonstrated efficacy in preventing tumor invasion in vitro.
- Inhibition of tumor growth and metastasis was observed in animal cancer models.
- Phase I clinical trials indicated that oral MMP inhibitors are well-tolerated in the short term.
Conclusions:
- Matrix metalloproteinase inhibitors represent a promising therapeutic approach for managing cancer invasion and metastasis.
- Further randomized clinical trials are warranted to establish the long-term efficacy and safety of MMP inhibitors in cancer patients.
